Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Avacopan

FDA-approved product (capsule, oral), marketed as Tavneos.

Registered studies
26
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Avacopan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anti-neutrophil antibody associated vasculitis
  • Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Granulomatosis with Polyangiitis
  • Microscopic polyangiitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Complement inhibitors
FDA pharmacologic class
Complement 5a Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis71.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

26registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Avacopan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Avacopan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube

    NCT07556484 · start 2026-08-01

    Registered record
    Registry ID
    NCT07556484
    Conditions
    Diffuse Alveolar Hemorrhage; Antineutrophil Cytoplasmic Antibody Positive Vasculitis
    Interventions
    Avacopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-08-01
    Completion
    2028-03
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Alveolar Hemorrhage; Antineutrophil Cytoplasmic Antibody Positive Vasculitis
    InterventionAvacopan
    PhasePhase 1
    Registry statusRecruiting

  • TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

    NCT07176546 · start 2026-05-22

    Registered record
    Registry ID
    NCT07176546
    Conditions
    Granulomatosis With Polyangiitis; Wegener' s; GPA
    Interventions
    Avacopan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-05-22
    Completion
    2030-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGranulomatosis With Polyangiitis; Wegener' s; GPA
    InterventionAvacopan; Placebo
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement

    NCT07373262 · start 2026-03-01

    Registered record
    Registry ID
    NCT07373262
    Conditions
    ANCA-Associated Vasculitis (AAV)
    Interventions
    Avacopan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2030-07-01
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionANCA-Associated Vasculitis (AAV)
    InterventionAvacopan; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

    NCT06676579 · start 2025-06-09

    Registered record
    Registry ID
    NCT06676579
    Conditions
    IgA Nephropathy (IgAN)
    Interventions
    Avacopan; Prednisone; Methylprednisolone (drug); Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-09
    Completion
    2029-03-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIgA Nephropathy (IgAN)
    InterventionAvacopan; Prednisone; Methylprednisolone (drug); Prednisolone
    PhasePhase 2
    Registry statusRecruiting

  • Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis

    NCT06611696 · start 2024-11-15

    Registered record
    Registry ID
    NCT06611696
    Conditions
    ANCA Associated Vasculitis (AAV)
    Interventions
    Avacopan, prednisolone and rituximab; Prednisolone and rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-11-15
    Completion
    2028-09-30
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionANCA Associated Vasculitis (AAV)
    InterventionAvacopan, prednisolone and rituximab; Prednisolone and rituximab
    PhasePhase 4
    Registry statusRecruiting

  • Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

    NCT06321601 · start 2024-10-22

    Registered record
    Registry ID
    NCT06321601
    Conditions
    Vasculitis
    Interventions
    Avacopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-10-22
    Completion
    2027-07-18
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasculitis
    InterventionAvacopan
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

    NCT06468826 · start 2024-06-18

    Registered record
    Registry ID
    NCT06468826
    Conditions
    End-Stage Renal Disease (ESRD)
    Interventions
    Avacopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-06-18
    Completion
    2024-10-05
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd-Stage Renal Disease (ESRD)
    InterventionAvacopan
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

    NCT06072482 · start 2024-02-07

    Registered record
    Registry ID
    NCT06072482
    Conditions
    Antineutrophil Cytoplasmic Antibody-associated Vasculitis
    Interventions
    Avacopan; Placebo; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-02-07
    Completion
    2036-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntineutrophil Cytoplasmic Antibody-associated Vasculitis
    InterventionAvacopan; Placebo; Standard of Care
    PhasePhase 4
    Registry statusRecruiting

  • Early-access Avacopan in Real-world ANCA-associated Vasculitis

    NCT06794827 · start 2023-11-01

    Registered record
    Registry ID
    NCT06794827
    Conditions
    ANCA Associated Vasculitis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-11-01
    Completion
    2026-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionANCA Associated Vasculitis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Avacostar - (PASS)

    NCT05897684 · start 2023-09-11

    Registered record
    Registry ID
    NCT05897684
    Conditions
    ANCA-associated Vasculitis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2023-09-11
    Completion
    2030-12-01
    Enrolment
    507

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionANCA-associated Vasculitis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • Special Drug Use-results Survey for Long-term Use（Avacopan）

    NCT06758271 · start 2022-07-29

    Registered record
    Registry ID
    NCT06758271
    Conditions
    Microscopic Polyangiitis (MPA); Granulomatosis With Polyangiitis (GPA)
    Interventions
    Avacopan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-07-29
    Completion
    2028-05-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMicroscopic Polyangiitis (MPA); Granulomatosis With Polyangiitis (GPA)
    InterventionAvacopan
    PhaseNot recorded
    Registry statusRecruiting

  • Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin

    NCT06207682 · start 2022-06-28

    Registered record
    Registry ID
    NCT06207682
    Conditions
    Healthy Volunteers
    Interventions
    Avacopan; Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-28
    Completion
    2022-08-11
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAvacopan; Simvastatin
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

    NCT05988034 · start 2019-11-08

    Registered record
    Registry ID
    NCT05988034
    Conditions
    Electrocardiography
    Interventions
    Avacopan; Moxifloxacin; Placebo for avacopan; Placebo for moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-11-08
    Completion
    2020-03-31
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionElectrocardiography
    InterventionAvacopan; Moxifloxacin; Placebo for avacopan; Placebo for moxifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

    NCT03852472 · start 2018-12-21

    Registered record
    Registry ID
    NCT03852472
    Conditions
    Hidradenitis Suppurativa; Acne Inversa
    Interventions
    Avacopan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-12-21
    Completion
    2021-03-09
    Enrolment
    435

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHidradenitis Suppurativa; Acne Inversa
    InterventionAvacopan; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

    NCT06004934 · start 2018-04-17

    Registered record
    Registry ID
    NCT06004934
    Conditions
    Hepatic Impairment
    Interventions
    Avacopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-04-17
    Completion
    2018-09-18
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionAvacopan
    PhasePhase 1
    Registry statusCompleted